Y-mAbs(US:YMAB)2025-05-13 11:26Revenue Performance - Reported net product revenues of $20.9 million for Q1 2025, an 8% increase from $19.4 million in Q1 2024[5] - U.S. DANYELZA net product revenues decreased by 28% to $13.4 million in Q1 2025, driven by clinical study enrollments and market dynamics[10] - Ex-U.S. DANYELZA net product revenues increased by $6.7 million to $7.5 million in Q1 2025, supported by new marketing initiatives in Western and Eastern Asia[11] - Total revenues for Q1 2025 were $20,904,000, an increase of 7.3% compared to $19,931,000 in Q1 2024[34] Financial Guidance - Management reiterates full year 2025 guidance with total revenues expected between $75 million and $90 million[25] - Second quarter 2025 total revenue guidance is projected to be between $17 million and $19 million[22] Expenses - Research and development expenses decreased to $11.4 million in Q1 2025 from $13.3 million in Q1 2024, primarily due to timing of clinical trials[17] - Selling, general, and administrative expenses increased to $13.1 million in Q1 2025 from $11.4 million in Q1 2024, attributed to higher personnel costs and business realignment expenses[18] - Total operating costs and expenses for Q1 2025 were $24,446,000, slightly down from $24,742,000 in Q1 2024, a decrease of 1.2%[34] - Research and development expenses for Q1 2025 were $11,359,000, a decrease of 14.4% compared to $13,267,000 in Q1 2024[34] - Selling, general, and administrative expenses increased to $13,087,000 in Q1 2025, up from $11,425,000 in Q1 2024, an increase of 14.5%[34] Profitability - The company reported a net loss of $5.2 million for Q1 2025, an improvement from a net loss of $6.6 million in Q1 2024[20] - Net loss for Q1 2025 was $5,196,000, a decrease from a net loss of $6,629,000 in Q1 2024, representing a 21.6% improvement[34] - Gross profit remained consistent at $17.9 million for Q1 2025, with gross margins decreasing to 86% from 89% in Q1 2024[16] - The company reported a gross profit of $17,903,000 for Q1 2025, compared to $17,834,000 in Q1 2024, reflecting a slight increase[34] Cash Position - Cash and cash equivalents as of March 31, 2025, were $60.3 million, with anticipated revenues expected to support operations into 2027[21] - Cash and cash equivalents decreased to $60,310,000 as of March 31, 2025, down from $67,234,000 at the end of 2024, a decline of 10.4%[32] Asset Management - The total assets decreased to $112,613,000 as of March 31, 2025, down from $119,904,000 at the end of 2024, a decline of 6.1%[32] Strategic Focus - The company anticipates continued growth in DANYELZA and plans to optimize its commercial potential[26] - The company is focused on expanding its clinical development efforts and exploring new strategic partnerships to enhance its market position[26]